FGFR4 and metabolic dysfunction-associated steatohepatitis: The authors held that fibroblast growth factor 19 - fibroblast growth factor receptor 4 (FGF19-FGFR4) pathway, which was target of lenvatinib, were involved in the tumorigenesis of non-alcoholic steatohepatitis- and alcohol-associated HCC and consequently, these HCCs responded better to lenvatinib.